Accordingly, multiple CAR-T products targeting CLDN18.2 are being preclinically or clinically evaluated, among which the most advanced second-generation CAR-T product, CT041, developed by CARsgen Therapeutics, has been reported to induce a 48.6% overall response rate (ORR) in treating a total of 37 cases of CLDN18.2-positive cancer with a 57.1% ORR in patients with GC in an ongoing phase 1 clinical trial (10, 11). The gene discussed is CLDN18; the disease is cancer.